Neuroscience, Neurology, Neuromodulation, Mental Health, Parkinson Disease.
trials, and meanwhile a data revolution coupled with a favorable reimbursement environment in oncology and rare disease has made it more lucrative for pharma companies to spend on these elements of their pipelines instead of on neuroscience. Several pharma companies have shuttered their